Drugs / lintuzumab
Trials 14
News releases announcing trial results or a regulatory action · 12
| Date | Issuer | Release |
|---|---|---|
| 2025-04-28 | Actinium Pharmaceuticals | Results Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting actiniumpharma.com ↗
Actimab-A significantly potentiated and prolonged efficacy in combination with standard of care targeted therapies including hypomethylating agent azacitidine, FLT3 and menin inhibitors in in-vivo AML models |
| 2023-11-06 | Actinium Pharmaceuticals | Results Actinium Presents Preclinical Data at SITC Demonstrating Actimab-A's Potential to Restore T Cell Immunity in the Solid Tumor Microenvironment Supporting Immunotherapy Combinations actiniumpharma.com ↗
Actimab-A reduced cancer patient-derived MDSCs in a dose-dependent manner ex vivo and decreased MDSC viability approximately two-fold greater than a non-radiolabeled CD33 antibody |
| 2023-03-16 | Actinium Pharmaceuticals | Results Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting actiniumpharma.com ↗
The abstracts highlight the multifaceted anti-cancer activity of CD33-targeted clinical-stage asset Actimab-A and enhanced anti-tumor effect of HER3-targeted, radiotherapy being developed in collaboration with AVEO Oncology, an LG Chem Company. |
| 2020-11-11 | Actinium Pharmaceuticals | Results Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials actiniumpharma.com ↗
Dr Atallah, as senior investigator, will review the Phase 1 data from the Actimab-A CLAG-M combination trial in relapsed or refractory acute myeloid leukemia (R/R AML) that demonstrated 100% remission in the third and planned final dose cohort. |
| 2020-11-04 | Actinium Pharmaceuticals | Results 100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML actiniumpharma.com ↗
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission. |
| 2020-11-04 | Actinium Pharmaceuticals | Results Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting actiniumpharma.com ↗
Combining Actimab-A (225Ac lintuzumab) with venetoclax in patients with R/R AML has an acceptable initial clinical safety profile at the initial subtherapeutic dose level of 0.5 μCi/kg of Actimab-A. |
| 2019-11-06 | Actinium Pharmaceuticals | Results Actinium Announces Interim Results from Phase 1 Actimab-A CLAG-M Combination Trial in Patients with Relapsed or Refractory AML Accepted for Presentation at ASH 2019 actiniumpharma.com ↗
83% of patients (5/6) receiving 0.50 uCi/kg of Actimab-A and CLAG-M in the second dosing cohort achieved a Complete Remission (CR), Complete Response with incomplete platelet recovery (CRp) or Complete Response with incomplete hematologic recovery (CRi) |
| 2019-04-08 | Actinium Pharmaceuticals | Results Actinium's Leading Clinical, Preclinical, Production and IP Efforts Related to Actinium-225 Highlighted at Preeminent Targeted Alpha Therapy International Symposium actiniumpharma.com ↗
The results of these studies using pharmacokinetic models determined that accelerator produced Ac-225 labeled to lintuzumab had a negligible impact in the context of therapy compared to generator produced Ac-225. |
| 2019-04-03 | Actinium Pharmaceuticals | Results Actinium Highlights Actimab-A and Venetoclax Synergies Observed in New Studies Presented at AACR actiniumpharma.com ↗
Actimab-A treatment of venetoclax resistant AML cells led to a decrease in MCL-1 levels. |
| 2018-12-03 | Actinium Pharmaceuticals | Results Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate actiniumpharma.com ↗
In this difficult to treat patient population, we are pleased to have observed this level of single-agent activity from Actimab-A with the benefit of minimal extramedullary toxicities. |
| 2013-12-09 | Actinium Pharmaceuticals | Results Encouraging Clinical Data From Multicenter Phase 1/2 Trial On Actinium's Actimab-A Presented At American Society Of Hematology Annual Meeting actiniumpharma.com ↗
Data demonstrated antileukemic effect in 67% of evaluable patients and 47% of patients treated across all dose levels. |
| 2013-12-02 | Actinium Pharmaceuticals | Results Actinium Pharmaceuticals Announces Additional Clinical Data From Multicenter Phase 1/2 Trial on Actinium's Actimab-A to Be Presented at American Society of Hematology Annual Meeting actiniumpharma.com ↗
Abstract presented at this year's ASH meeting will report the initial data from the study demonstrating that administration of Actimab-A (monoclonal antibody HuM195 labeled with actinium 225) in fractionated doses is feasible, safe and has antileukemic activity. |
All press releases naming this drug 12 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | lintuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00006045 ↗ |
| Known as | 90Y-MOAB HuM195 | “yttrium-90-labeled humanized monoclonal antibody M195 (90Y-MOAB HuM195)” NCT00002890 ↗ |
| Known as | HuM-195/rGel | “The goal of this clinical research study is to find the highest safe dose of the anti-CD33 immunotoxin HuM-195/rGel that can be given to patients with advanced myeloid malignancies.” NCT00038051 ↗ |
| Known as | HuM195 | “A multi-institutional, phase 1 dose-escalation trial of lintuzumab (humanized anti-CD33 antibody; SGN-33, HuM195) was performed in patients with CD33-positive myeloid malignancies.” PMID 19557623 ↗ Aug 20094“Lintuzumab (SGN-33; HuM195) is a humanized monoclonal antibody directed against CD33, which is expressed on the majority of myeloblasts in acute myeloid leukemia.” PMID 22801961 ↗ Jul 2012 “In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses” NCT02575963 ↗ “yttrium-90-labeled humanized monoclonal antibody M195 (90Y-MOAB HuM195)” NCT00002890 ↗ |
| Known as | M195 | “yttrium-90-labeled humanized monoclonal antibody M195 (90Y-MOAB HuM195)” NCT00002890 ↗ |
| Action | Deplete | “The immunotoxin is designed to selectively destroy myeloid leukemia cells.” NCT00038051 ↗ |
| Modality | Monoclonal antibody | “humanized anti-CD33 monoclonal antibody” NCT00002609 ↗ |
| Route | Intravenous | “All patients receive a single intravenous dose of 90Y-MOAB HuM195.” NCT00002890 ↗ |
| Target | CD33 | “anti-CD33 monoclonal antibody” NCT00002609 ↗ |